Highlights

  • Micro-X (ASX:MX1) develops compact X-ray imaging systems using carbon nanotube technology.
  • The company’s products include mobile medical imaging and security screening solutions.
  • Rover portable X-ray systems provide an established commercial product base.
  • Commercialisation, regulatory progress and funding remain important areas to monitor.

Micro-X Limited (ASX:MX1) is an Adelaide-based medical and security imaging company developing compact X-ray technologies based on cold-cathode carbon nanotube sources. The company is focused on creating smaller, lighter and lower-power imaging systems for applications including healthcare, security screening and remote imaging environments.

Carbon Nanotube X-Ray Technology

Micro-X’s technology replaces traditional heated electron sources with electronically controlled carbon nanotube-based systems. This approach allows X-ray equipment to be designed in smaller and more portable formats compared with conventional imaging systems.

The company applies this technology across multiple products, including mobile medical imaging equipment and security solutions. The portability of these systems is central to their intended use in locations where traditional fixed imaging equipment may not be practical.

Medical Imaging Product Development

Micro-X’s Rover mobile X-ray system is an established product designed for healthcare environments. The company has expanded sales of the system internationally and continues to develop additional medical imaging applications.

The company is also developing a lightweight Head CT system designed for potential use in ambulances and regional healthcare settings. Earlier access to brain imaging could support faster assessment of stroke patients, although the product remains in development.

Security Imaging Opportunities

Beyond healthcare, Micro-X is developing security imaging solutions using its compact X-ray technology. The company has participated in development programmes focused on automated passenger screening and software-based threat detection.

These projects involve collaboration and staged development activities, with future commercial outcomes dependent on technical progress, programme requirements and adoption.

Funding and Commercial Considerations

Micro-X continues to invest in product development, Manufacturing capability and commercialisation activities. The company has used Capital raising activities to support medical imaging development, manufacturing expansion and Working Capital requirements.

As the company progresses multiple product areas, managing development costs and converting programmes into commercial Revenue remain important considerations.

Key Insights

Micro-X is building a portfolio around portable X-ray technology designed for healthcare and security applications. The company’s future progress depends on expanding commercial adoption, advancing products through regulatory pathways and translating development programmes into repeatable revenue streams.